Lithium Citrate
FDA-approved product (syrup, oral), marketed as Lithium Citrate, Lithonate, Potassium Citrate and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia (phenotype)
- Bipolar I disorder
- Major depressive disorder
- Renal tubular acidosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Potassium; Salt solutions
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Lithium Citrate, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA11.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae10.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lithium Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
NCT00251316 · start 2005-11
Registered record
- Registry ID
- NCT00251316
- Conditions
- Thyroid Cancer; Differentiated Thyroid Carcinoma
- Interventions
- Lithium Carbonate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2011-12
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThyroid Cancer; Differentiated Thyroid CarcinomaInterventionLithium Carbonate; PlaceboPhasePhase 2Registry statusCompletedTreatment of Mania Symptoms With Drug Therapy
NCT00183443 · start 2005-02
Registered record
- Registry ID
- NCT00183443
- Conditions
- Bipolar Disorder; Schizophrenia
- Interventions
- Divalproex-extended release (DVP-ER); Lithium; Quetiapine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-02
- Completion
- 2010-11
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar Disorder; SchizophreniaInterventionDivalproex-extended release (DVP-ER); Lithium; QuetiapinePhasePhase 3Registry statusCompletedOlanzapine Versus Comparator in the Treatment of Bipolar Disorder
NCT00485680 · start 2003-12
Registered record
- Registry ID
- NCT00485680
- Conditions
- Bipolar Disorder
- Interventions
- Olanzapine Hydrochloride; Lithium Carbonate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-12
- Completion
- 2005-06
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar DisorderInterventionOlanzapine Hydrochloride; Lithium CarbonatePhasePhase 3Registry statusCompletedAtypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode
NCT01977300 · start 2003-01
Registered record
- Registry ID
- NCT01977300
- Conditions
- Bipolar I Disorder
- Interventions
- Valproate; Lithium; Risperidone; Olanzapine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2011-08
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar I DisorderInterventionValproate; Lithium; Risperidone; Olanzapine +1 morePhasePhase 3Registry statusCompletedBioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions
NCT00601575 · start 2002-10
Registered record
- Registry ID
- NCT00601575
- Conditions
- Bipolar Disorder
- Interventions
- Lithium
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-10
- Completion
- 2002-11
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBipolar DisorderInterventionLithiumPhaseNot applicableRegistry statusCompleted